Protein kinases and phosphatases as therapeutic targets in cancer

Clinical and Translational Oncology

Volumn 8, Issue 3, 2006, Pages 153-160

  Ventura, Juan José ^a   Nebreda, Ángel R ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 HYDROXYSTAUROSPORINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANTINEOPLASTIC AGENT; BOSUTINIB; CYCLIN DEPENDENT KINASE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; FLAVOPIRIDOL; HESPERADIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; ROSCOVITINE; UNINDEXED DRUG; WORTMANNIN; PHOSPHATASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; LEUKEMIA REMISSION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; ENZYMOLOGY; NEOPLASM; PHYSIOLOGY; REVIEW;

HUMANS; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 33747097252     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0005-0     Document Type: Article

References (45)

1. Manning G, Whyte DB, Martínez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912-34.
2. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296-313.
3. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:509-15.
4. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: Insights into drug design from structure. Science. 2004; 303:1800-5.
5. Biondi RM, Nebrada AR. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J. 2003;372:1-13.
6. Ducruet AP, Vogt A, Wipf P, Lazo JS. Dual specificity protein phosphatases: Therapeutic targets for cancer and Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2005; 45:725-50.
7. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;355:172-87.
8. Fischer OM, Streit S, Hart S, Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol. 2003;7:490-5.
9. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;105:211-25.
10. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-AbI tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5:33-44.
11. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;505:1163-7.
12. Watanabe D, Ezoe S, Fujimoto M, et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol. 2004;126:726-35.
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;544:785-92.
14. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344;1038-42.
15. Martinelli G, Soverini S, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 2005;19:1872-9.
16. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;505:399-401.
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;547:472-80.
18. Malumbres M., Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30:630-41.
19. Malumbres M, Barbacid M. Is Cyclin D1-CDK4 kinase a bona fide cancer target?. Cancer Cell. 2006;9:2-4.
20. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5:566-73.
21. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421-9.
22. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mototic checkpoint, adaptation, and cell death. Cancer Cell. 2005;8: 7-12.
23. Eckerdt F, Yuan, J, Strebhardt K. Polo-like kinase and oncogenesis. Oncogene. 2005; 24:267-76.
24. Giet R, Petretti C., Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol. 2005;15: 241-50.
25. Gumiredy K, Reddy MV, Consenza SC, et al. ONO 1910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005;7:275-86.
26. Andrews PD. Aurora kinases: Shining lights on the therapeutic horizon? Oncogene. 2005;24:5005-15.
27. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4:927-36.
28. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455-64.
29. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene. 2005;24:7482-92.
30. Kumar CC, Madison V: AKT crystal structure and AKT-specific inhibitors. Oncogene. 2005;24:7493-501.
31. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle. 2005;4:1540-9.
32. Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin Oncol. 2004; 51:10-7; discussion 33.
33. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
34. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15:463-9.
35. Beeram M, Patnaik A, Rowinsky EK. Raf: A strategic target for therapeutic development against cancer. J Clin Oncol. 2005; 23:6771-90.
36. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4:937-47.
37. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;459:558-62.
38. Bulavin DV, Fornace AJ, Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95-118.
39. Olson JM, Hallahan AR. p38 MAP kinase: A convergence point in cancer therapy. Trends Mol Med. 2004;10:125-9.
40. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: From junk to gold? Nat Rev Drug Discov. 2003;2:554-65.
41. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
42. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117:699-711.
43. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem. Biol. 2004;11: 1043-51.
44. Gallego M, Virshup DM. Protein serine/threonine phosphatases: Life, death, and sleeping. Curr Opin Cell Biol. 2005;17: 197-202.
45. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor supressor pathway. J Clin Oncol. 2004;22: 2954-65.